BioMark Diagnostics (TSE:BUX) has released an update.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
BioMark Diagnostics has made a significant advancement in breast cancer diagnosis with its liquid biopsy platform capable of predicting estrogen receptor status with 93% accuracy. This breakthrough promises to revolutionize breast cancer diagnosis and treatment, potentially saving lives through earlier diagnoses and personalized treatment options.
For further insights into TSE:BUX stock, check out TipRanks’ Stock Analysis page.